The importance of nuance when considering different subtle flavours

Just when we thought we had BTK inhibition figured out, along come the protein degraders to disrupt the party!

While covalent BTK inhibitors transformed CLL treatment and non-covalent inhibitors aimed to tackle resistance, a new class of drugs is taking a more radical approach: why just inhibit BTK when you can eliminate it entirely?

At ASH this month, two BTK degraders stepped into the spotlight. With response rates approaching 80% in heavily pretreated patients – including those with notorious resistance mutations – both BGB-16673 and NX-5948 are challenging our expectations of what’s possible in relapsed/refractory CLL.

As the dust settles on these early phase 1 results, the real story may lie in the nuances…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by